PD-1 Cellular Nanovesicles Carrying Gemcitabine to Inhibit the Proliferation of Triple Negative Breast Cancer Cell

• Main Authors: Hualian Zha (Author), Zhanxue Xu (Author), Xichao Xu (Author), Xingyu Lu (Author), Peilin Shi (Author), Youmei Xiao (Author), Hsiang-I Tsai (Author), Dandan Su (Author), Fang Cheng (Author), Xiaoli Cheng (Author), Hongbo Chen (Author)
• Format: Book
• Published: MDPI AG, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

PD-1 inhibitor Keytruda combined with chemotherapy for Triple-negative breast cancer (TNBC) has been approved for FDA, successfully representing the combination therapy of immunotherapy and chemotherapy for the first time in 2020. However, PD-L1 inhibitor Tecentriq combined with albumin paclitaxel u...